caa a22 4500 606248056 CHVBK 20210128101348.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s12262-015-1361-1 doi (NATIONALLICENCE)springer-10.1007/s12262-015-1361-1 Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer [Elektronische Daten] [Matthew Reilley, Rachna Shroff, Gauri Varadhachary] The delivery of postoperative combined modality adjuvant therapy for completely resected pancreatic adenocarcinoma was initially shown to be beneficial based on a prospective, randomized trial published 30years ago. Since then, oncologists have debated whether chemotherapy alone, chemoradiation, or both are optimal adjuvant therapies following pancreatectomy for pancreatic ductal adenocarcinomas (PDAC). No global consensus has emerged, and there is no one superior modality despite randomized trials in part, to poor trial design, poor patient selection, and poor therapy options itself. We need to have a disciplined approach to the selection of patients for pancreatectomy, pathologic assessment of surgical resection margins, and postoperative (pre-treatment) imaging. In the era of the multidetector CT optimized for pancreatic imaging, tumors of "borderline resectability” have emerged as a distinct subset of PDAC. The attempt to standardize the definition of borderline resectable is a work in progress and modified with time. This distinction (between resectable and borderline resectable) is essential to minimize potentially confounding results of clinical trials. Additionally, preoperative therapy is not only preferred but mandatory in a large population of borderline resectable patients. Ultimately, as we develop more effective systemic therapies for PDAC, proceeding with surgery after a period of induction therapy will be even more compelling especially if there is a clear positive impact on overall survival. Association of Surgeons of India, 2015 Pancreatic adenocarcinoma nationallicence Borderline resectable pancreatic adenocarcinoma nationallicence Preoperative treatment nationallicence Neoadjuvant treatment nationallicence Reilley Matthew Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, TX, USA aut Shroff Rachna Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd. Unit 426, 77030, Houston, TX, USA aut Varadhachary Gauri Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd. Unit 426, 77030, Houston, TX, USA aut Indian Journal of Surgery Springer India 77/5(2015-10-01), 403-408 0972-2068 77:5<403 2015 77 12262 https://doi.org/10.1007/s12262-015-1361-1 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s12262-015-1361-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Reilley Matthew Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, TX, USA aut NATIONALLICENCE 700 1- Shroff Rachna Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd. Unit 426, 77030, Houston, TX, USA aut NATIONALLICENCE 700 1- Varadhachary Gauri Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd. Unit 426, 77030, Houston, TX, USA aut NATIONALLICENCE 773 0- Indian Journal of Surgery Springer India 77/5(2015-10-01), 403-408 0972-2068 77:5<403 2015 77 12262